Show Full Stories
XTo view all stories in expanded form, please subscribe.
Henry Schein CSO Mlotek sells nearly 25,000 common shares » 16:2105/2305/23/23
In a regulatory filing,…
In a regulatory filing, Henry Schein chief strategic officer Mark Mlotek disclosed the sale of 24,747 common shares of the company on May 19 at a price of $76.68 per share.
|Over a week ago|
Henry Schein price target lowered to $90 from $92 at Barrington » 09:4805/1005/10/23
Barrington lowered the…
Barrington lowered the firm's price target on Henry Schein to $90 from $92 and keeps an Outperform rating on the shares. The company reported "solid" Q1 results but reduced its fiscal 2023 outlook slightly to reflect recent acquisitions, the analyst tells investors in a research note.
Henry Schein cuts FY23 adjusted EPS view to $5.18-$5.35 from $5.25-$5.42 » 06:3305/0905/09/23
FY23 consensus $5.33.…
FY23 consensus $5.33. 2023 sales growth is expected to be approximately 1% to 3% over 2022, unchanged from prior guidance, consensus $12.83B.
Henry Schein reports Q1 adjusted EPS $1.21, consensus $1.23 » 06:3005/0905/09/23
Reports Q1 revenue $3.1B,…
Reports Q1 revenue $3.1B, consensus $3.09B.
Henry Schein acquires Regional Health Care Group » 18:2105/0705/07/23
Henry Schein announced on…
Henry Schein announced on Sunday the acquisition of Regional Health Care Group, a medical products distribution company serving public- and private-sector customers in Australia and New Zealand. Henry Schein acquired RHCG, which had sales for the 12 months ended June 30, 2022, of $42M, from Maurie and Bernard Stang, who wholly owned the company and retain a minority interest in Henry Schein's ANZ dental business. Henry Schein expects the transaction to be neutral to 2023 diluted earnings per share when excluding amortization expenses and accretive thereafter. Financial terms were not disclosed.
|Over a month ago|
Henry Schein price target raised to $82 from $75 at UBS » 07:2903/0703/07/23
UBS analyst Kevin…
UBS analyst Kevin Caliendo raised the firm's price target on Henry Schein to $82 from $75 and keeps a Neutral rating on the shares. The firm believes the company's longer-term targets of 6%-8% revenue growth and 8%-11% EPS growth seem achievable, the analyst tells investors in a research note.
Henry Schein to hold a virtual investor meeting » 08:5502/2702/27/23
Henry Schein to detail strategic plan, long-term goals at investor meeting » 06:3202/2702/27/23
Henry Schein is hosting…
Henry Schein is hosting an Investor Meeting today in New York City at 9 a.m. EST, where executive leadership will provide an overview of the Company's BOLD+1 Strategic Plan for sustainable growth and details about the Company's long-term financial goals. Henry Schein's management team will present the Company's value-creation strategy and long-term financial goals, including: A deep dive into its BOLD+1 Strategic Plan and the key initiatives underway to accelerate growth and margin expansion; The significant progress made to date related to: Expanding the Specialty Products and Technology and Value-added Service businesses; Delivering sustainable growth; Driving digital transformation; Investing in people and culture as we advance our ESG priorities; and Additional discussion of the recently announced 2023 financial guidance, estimates of relevant market sizes and growth, and key drivers of the Company's long-term financial goals.
Henry Schein to hold a virtual investor meeting » 04:5502/2702/27/23
|Over a quarter ago|
Henry Schein to hold a virtual investor meeting » 17:1002/2602/26/23